Deals channel feed

Black­stone throws $250M be­hind In­tel­lia-Cellex quest to com­bine CRISPR and con­trol­lable CAR-Ts

4 years ago

Al­fasig­ma snares EU rights to blood clot­ting an­ti­body on the hunt for pa­tients tak­ing As­traZeneca's Bril­in­ta

4 years ago

They went from dai­ly to once every two months. But how much longer act­ing can HIV meds be? Vi­iV en­lists Halozyme's tech to find out

4 years ago

The dig­i­tal health field con­tin­ues to boom as Soft­Bank-backed start­up hits uni­corn sta­tus in SPAC re­verse merg­er

4 years ago
Financing

Or­phan drug spe­cial­ist Hori­zon looks to dou­ble down on its gout ex­per­tise with ac­quired rights to Ar­row­head­'s RNAi med

4 years ago

Bris­tol My­ers breaks the bank on Ei­sai's fo­late re­cep­tor ADC drug, lay­ing out more than $3B+ for rights

4 years ago

In an ef­fort to safe­ly de­liv­er mR­NA, Stan­ford Uni­ver­si­ty teams up with Ger­man biotech Evonik

4 years ago
Manufacturing

As it awaits piv­otal re­view of lead drug, Fi­bro­Gen bol­sters its ear­ly pipeline with li­cens­ing deal for galectin pro­gram

4 years ago

Dana­her strikes deal to buy boom­ing next-gen man­u­fac­tur­er Alde­vron for $9.6B

4 years ago
Manufacturing

Chi­nese on­col­o­gy spe­cial­ist Zai Lab bro­kers a deal with Macro­Gen­ics for up to 4 bis­pecifics with a mod­est down pay­ment

4 years ago

Amid slug­gish sales and du­el­ing law­suits, No­var­tis bows out of Am­gen part­ner­ship, slash­es staff

4 years ago
Pharma

Ex­sci­en­tia spends Soft­Bank's cash in bid to edge out AI ri­vals

4 years ago
AI

CRISPR Ther­a­peu­tics takes a swing at ALS gene edit­ing in dis­cov­ery deal with AAV up­start Cap­si­da

4 years ago

Top an­a­lyst maps a rocky road for Ver­tex — un­less they adopt a $10B M&A cam­paign to save the pipeline

4 years ago
Pharma

Hal Bar­ron gam­bles $625M cash on high-wire TIG­IT act, throw­ing Glax­o­SmithK­line in­to heat­ed race and com­plet­ing next-gen I/O trin­i­ty

4 years ago

Sid Mukher­jee's Vor taps a CAR-T de­vel­op­ment part­ner to strap to its at­tempt at bet­ter stem cell trans­plants

4 years ago
Cell/Gene Tx

Flag­ship and Khosla Ven­tures team up for biotech's lat­est SPAC, with Va­lo Health win­ning a blank check tick­et to Nas­daq

4 years ago
Financing
AI

Roivan­t's da­ta spin­out merges with ri­val in $7B deal

4 years ago

BeiGene dives in on nat­ur­al killer cells with dis­cov­ery pact for small biotech's stem cell-based plat­form

4 years ago

On a con­tin­ued hunt for Parkin­son's break­throughs, Ab­b­Vie turns to a biotech in its port­fo­lio

4 years ago

Keen to turn a new page, In­di­v­ior branch­es out, pick­ing up an op­tion for cannabis ad­dic­tion drug

4 years ago

J&J breaks off al­liance with ar­genx, drop­ping CD70 AML drug and ax­ing $1.3B in biobucks

5 years ago

'Au­ton­o­my with bridges': The chief ar­chi­tect of the Alex­ion buy­out is now head­ed over to take com­mand. Here's what he's think­ing

5 years ago

Bay­er dou­bles down on ra­dio­ther­a­py with ac­qui­si­tions of 2 tiny biotech play­ers built around re­search from Cor­nell

5 years ago
First page Previous page 75767778798081 Next page Last page
A service from the Financial Times